1607828-43-2

Basic information

• Product Name: N-(4-bromo-5-chloro-2-methylphenyl)-acetamide
• Synonyms: N-(4-bromo-5-chloro-2-methylphenyl)-acetamide
• CAS NO: 1607828-43-2
• Molecular Weight: 262.534
• Mol File: 1607828-43-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-bromo-5-chloro-2-methylphenyl)-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-bromo-5-chloro-2-methylphenyl)-acetamide(1607828-43-2)
• EPA Substance Registry System: N-(4-bromo-5-chloro-2-methylphenyl)-acetamide(1607828-43-2)

Safety Data

• Hazardous Substances Data: 1607828-43-2(Hazardous Substances Data)

Upstream product

• 30273-47-3 4-bromo-5-chloro-2-methyl aniline 
• 108-24-7 acetic anhydride 
• 5900-55-0 N-(5-chloro-2-methylphenyl)acetamide 

Downstream Products

• 1607828-44-3 N-acetyl-5-bromo-4-chloroanthranilic acid 
• 50419-88-0 2-amino-5-bromo-4-chlorobenzene carboxylic acid 
• 1607828-49-8 5-bromo-4-chloro-N-[(allyloxycarbonyl)methyl]anthranilic acid allyl ester 
• 93863-88-8 (5-bromo-6-chloroindol-3-yl)-β-D-galactopyranoside 
• 1312008-66-4 1-(5-bromo-6-chloroindazol-1-yl)ethanone 
• 1613505-06-8 6-chloro-5-(2-(trifluoromethyl)phenyl)-1H-indazole 

Relevant articles and documents

SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CR1 or N; and G, A, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Discovery, optimization, and biological evaluation of 5-(2- (trifluoromethyl)phenyl)indazoles as a novel class of transient receptor potential A1 (TRPA1) antagonists

A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.